Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Johns Hopkins Genomics, |
RCV001200878 | SCV001371782 | uncertain significance | Immunodeficiency, common variable, 7 | 2020-01-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001200878 | SCV002291225 | pathogenic | Immunodeficiency, common variable, 7 | 2022-11-03 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 932909). This variant has not been reported in the literature in individuals affected with CR2-related conditions. This variant is present in population databases (rs141472681, gnomAD 0.008%). This sequence change creates a premature translational stop signal (p.Arg220*) in the CR2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CR2 are known to be pathogenic (PMID: 26325596, 28499783). |
Prevention |
RCV004548053 | SCV004117376 | likely pathogenic | CR2-related disorder | 2023-05-23 | criteria provided, single submitter | clinical testing | The CR2 c.658C>T variant is predicted to result in premature protein termination (p.Arg220*). To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0080% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-207642168-C-T). Nonsense variants in CR2 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |